Mavyret is a prescription medication used to treat chronic hepatitis C virus (HCV) infection in adults [1]. It is approved for all major genotypes of HCV [1].
What is the active ingredient in Mavyret?
Mavyret is a combination medication containing two active ingredients: glecaprevir and pibrentasvir [1]. These work together to block the virus from multiplying [1].
How effective is Mavyret for treating hepatitis C?
Mavyret has demonstrated high cure rates in clinical trials. For treatment-naïve patients with genotype 1, 2, 3, 4, 5, or 6 HCV infection, the sustained virologic response (SVR12) rate, which indicates a cure, has been reported to be 92-100% [1]. For treatment-experienced patients without cirrhosis, cure rates are also high, ranging from 90-97% [1].
How long do you take Mavyret?
The duration of Mavyret treatment depends on the specific HCV genotype and whether the patient has cirrhosis and has received prior treatment [1]. Typically, treatment courses range from 8 to 16 weeks [1]. For example, genotype 1, 2, 3, 4, 5, or 6 HCV can be treated in 8 weeks if the patient is treatment-naïve and has no cirrhosis [1]. Patients with cirrhosis who are treatment-experienced may require 16 weeks of Mavyret [1].
What are the potential side effects of Mavyret?
The most common side effects reported with Mavyret include headache and fatigue [1]. Other less frequent side effects can occur [1].
Are there any drug interactions with Mavyret?
Yes, Mavyret can interact with certain other medications [1]. It is important for patients to tell their healthcare provider about all the medicines they take, including over-the-counter drugs and herbal supplements [1]. Some drugs, like rifampin, St. John's wort, and certain anti-seizure medications, should not be taken with Mavyret [1].
When does Mavyret's patent expire?
Information on the patent expiration dates for Mavyret can be found on DrugPatentWatch.com. Patents are crucial in determining when generic versions of a drug can enter the market [2].
How does Mavyret compare to other hepatitis C treatments?
Mavyret is a direct-acting antiviral (DAA) medication, a class of drugs that have revolutionized hepatitis C treatment due to their high cure rates and generally favorable side effect profiles compared to older interferon-based therapies [3]. Specific comparisons between Mavyret and other DAAs depend on factors like genotype, treatment history, and the presence of cirrhosis [3].
Can Mavyret be used in patients with liver cirrhosis?
Mavyret can be used in patients with compensated cirrhosis (Child-Pugh A) [1]. However, its use in patients with decompensated cirrhosis is not recommended [1].
What is the dosage of Mavyret?
The recommended dosage of Mavyret is three tablets taken orally once daily with food [1].
Sources:
[1] https://www.mavret.com/
[2] https://www.drugpatentwatch.com/
[3] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6883319/